Clinical Prediction Score for Successful Weaning from Noninvasive Positive Pressure Ventilation (NIPPV) in Emergency Department; a Retrospective Cohort Study

Sittichok Leela-amorns1, Chavin Triganjananun1, Chaiyaporn Yuksen2*, Chetsadakon Jenpanitpong2, Sorawich Watcharakitpaisan2

1. Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 111 Moo 14, Bang Pla, Bang Phli, Samut Prakarn 10540, Thailand.
2. Department of Emergency Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Abstract: Introduction: Due to the lack of in-hospital beds, some patients with acute cardiogenic pulmonary edema are initiated and weaned off noninvasive positive pressure ventilation (NIPPV) at the emergency department (ED). This study aimed to develop a clinical score to predict successful weaning from NIPPV in these patients. Methods: This retrospective cohort study was conducted on patients with acute cardiogenic pulmonary edema who received NIPPV at the ED of Ramathibodi Hospital, Bangkok, Thailand. Multivariable logistic regression analysis was used to develop a predictive model for weaning from NIPPV. Results: 355 patients with acute cardiogenic pulmonary edema treated with NIPPV were studied (107 (30.14%) failed to be weaned). The significant risk factors of weaning failure based on multivariate analysis were age > 75 years (OR: 3.1, 95% CI: 1.15–8.33, p = 0.025), pneumonia (OR: 2.72, 95% CI: 1.39–5.31, p = 0.003), pulse rate > 80 bpm before NIPPV (OR: 1.74, 95% CI: 1.04–2.91, p = 0.033), and a urinary output < 150 cc/h while using NIPPV (OR: 2.93, 95% CI: 1.74–4.91, p < 0.001). In addition, clinically significant risk factors for weaning from NIPPV were age 60 – 75 years, respiratory rate > 26 breaths/min before weaning and oxygen saturation of < 97% as assessed by pulse oximetry before weaning from NIPPV. Since the lowest coefficient obtained was 0.46, the scores were split into groups of 0.5 points for each factor. Based on the area under the receiver operating characteristic (ROC) curve (71.3% (95% CI: 66.0–75.7%)), the cut point of risk score was divided into the low-risk with positive likelihood ratio of 0.48 (95% CI 0.33–0.69, P <0.001), the moderate-risk with positive likelihood ratio of 0.74 (95%CI 0.52–1.05, P = 0.080), and the high-risk group with positive likelihood ratio of 3.41 (95%CI 2.39–4.88, P <0.001) for predicting weaning failure. Conclusion: In patients with acute cardiogenic pulmonary edema under the NIPPV, weaning is associated with a significant increasing risk of failure in age >75, presence of pneumonia, heart rate > 80 bpm before weaning, and urinary output < 150 cc/h during ventilation. Based on the designed model in this study, patients with score ≤ 3.5, 4–5, and > 5 points were in low, moderate, and severe risk of weaning failure, respectively.

Keywords: Noninvasive Ventilation; ventilator weaning; continuous positive airway pressure; emergency service, hospital; intubation

1. Introduction

Acute cardiogenic pulmonary edema is a common cause of referring to emergency departments (EDs) worldwide. In the United States, approximately 6 million patients have acute cardiogenic pulmonary edema annually (1, 2). At Ramathibodi Hospital, Thailand, more than 450 patients are diagnosed with acute cardiogenic pulmonary edema annually and require a noninvasive ventilator.
The clinical diagnostic criteria for diagnosing acute cardiogenic pulmonary edema based on the European Society of Cardiology (ESC) guidelines are as follows: acute respiratory distress (acute increase in the work of breathing, considerable tachypnea, respiratory rate > 25 breaths/min, use of accessory muscles, or abdominal paradox), findings from a physical examination (crackles plus wheezing in the lungs or a third heart sound), and history of orthopnea and respiratory failure (oxygen saturation in room air by pulse oximetry < 60 mmHg, PaCO2 > 45 mmHg, or PaO2 / fraction of inspired oxygen (FiO2) < 300 mmHg) (3).

The diagnostic confirmation of acute cardiogenic pulmonary edema consists of at least two of the following: clear signs of pulmonary congestion on chest radiography or a computed tomography scan; multiple B-lines ≥ 3; B-lines in two chest zones on each hemithorax as shown by lung ultrasound; elevated pulmonary capillary pressure on catheterization; increased total lung water on pulse contour and a thermolulation analysis system; signs of elevated filling pressure on echocardiography; and a significant elevation in natriuretic peptide concentrations (BNP > 400 pg/ml or N-proBNP > 900 pg/ml or 1800 pg/ml in > 75 years)

There are various etiologies of acute cardiogenic pulmonary edema, such as cardiac ischemia, acute coronary disease, valvular heart disease, hypertensive emergency, arrhythmias, and tamponade (4). Symptoms of this condition include dyspnea, shortness of breath, leg edema, and desaturation (5-7).

If a patient has mild symptoms of pulmonary edema, treatment involves oxygenation, a vasodilator drug, or a diuretic drug (1). In more severe cases, a noninvasive ventilator is applied to the patient to support ventilation and decrease the work of the breathing muscles.

Noninvasive ventilators continuously create positive airway pressure, decrease venous return to the heart, decrease afterload, reduce left ventricular pressure, and improve clinical outcomes in patients with acute cardiogenic pulmonary edema (8-10). Moreover, using noninvasive ventilators reduces intubation rate, the risk of post-intubation complications (e.g., infection, barotrauma, laryngeal edema, and tracheal stenosis), and hospital mortality in severe acute cardiogenic pulmonary edema (9, 11). Therefore, noninvasive ventilators are useful for treating acute cardiogenic pulmonary edema and have been suggested as the first-line strategy. When the patients’ clinical outcome improves, they can be weaned off the noninvasive ventilator. Currently, Ramathibodi Hospital is experiencing the problem of a limitation of inpatient beds. This situation has led to ED overcrowding with critical patients receiving noninvasive ventilation, including those with acute cardiogenic pulmonary edema. Treatment is performed in a resuscitation zone, including weaning from noninvasive ventilation in acute cardiogenic edema. Noninvasive ventilation’s rate of weaning failure (patients continue noninvasive ventilation or are intubated after weaning from noninvasive ventilation) is > 250 cases/year. Disadvantages of prolonged use of a noninvasive ventilator include gastric distension, aspiration, hypotension and coughing (12). A weaning failure can make patients feel uncomfortable. There is still a lack of evidence for using parameters to improve judgment and a successful outcome of weaning from noninvasive ventilation. This study aimed to develop a clinical score to predict the risk of failure to wean from noninvasive positive pressure ventilation (NIPPV) in patients with cardiogenic pulmonary edema.

2. Methods

2.1. Study design and setting

This is a retrospective cohort study to design a diagnostic prediction model, which was conducted on patients with acute cardiogenic pulmonary edema who received NIPPV for treatment at the ED of Ramathibodi Hospital, a university-affiliated super tertiary care hospital in Bangkok, Thailand, from January 2017 to December 2019. This study was approved by the Faculty of Medicine, Committee on Human Rights Related to Research Involving Human Subjects, Ramathibodi Hospital, Mahidol University (COA. NO MURA2020/972). The ethics committee waived obtaining consent for this research as the patients’ medical records were used for data gathering and a statement covering patient data confidentiality and compliance with the Declaration of Helsinki was provided.

2.2. Participants

We included patients with acute cardiogenic pulmonary edema who received NIPPV for treatment and weaning from NIPPV was attempted at the ED. Data were collected from the Ramathibodi Hospital database and emergency medical records.

The eligibility criteria were patients older than 18 years, a clinical diagnosis of acute respiratory failure caused by acute cardiogenic pulmonary edema based on ESC criteria, and the requirement of noninvasive ventilation and weaning from noninvasive ventilation at the ED. The exclusion criteria were use of noninvasive ventilation within the previous 24 hours, hospitalization due to trauma or having a history of surgery in facial/oral/trachea/laryngeal areas within the past one month, hemodynamic instability, inability to protect the airways, excessive secretion, lack of cooperation, inability to fit the mask, and receiving hemodialysis or peritoneal dialysis during treatment.

2.3. Data gathering and outcome measures

The variables for determining clinical scoring of successful weaning from noninvasive ventilation were recorded for all...
eligible patients, including baseline characteristics and potential clinical factors for successful weaning from non-invasive ventilation. Initial vital signs (respiratory rate, blood pressure, heart rate, body temperature, and SpO2) were measured when the patient arrived at the triage zone of the ED. Vital signs before weaning were measured before deciding to discontinue NIPPV for the patient. Laboratory variables (white blood cell count, hemoglobin, hematocrit, blood urea nitrogen, sodium, potassium, and pro B-type natriuretic peptide (Pro-BNP)) were measured within 30 mins after the patient arrived at the ED. The first troponin blood test was collected 30 minutes after the patient arrived at the ED, and the second test was collected 3 hours later. The arterial blood gases (pH, PaO2, PaCO2, HCO3, lactate, oxygen saturation) were measured before the patient applied NIPPV and within 90 minutes before discontinuing NIPPV. The door to NIPPV was recorded as the time interval between when the patient arrived at the ED and when NIPPV was applied. The duration of NIPPV was the total time the patient was using NIPPV in ED.

The setting of NIPPV (mode of NIPPV, inspiratory pressure, expiratory pressure, pressure support, positive end-expiratory pressure (PEEP), FiO2) was recorded when the emergency resident or emergency physician initiated and before weaning of NIPPV. The diuretic dose was the accumulated dose of furosemide that the patient was given while receiving NIPPV. The urinary output was the total amount of urine during the period the patient received NIPPV. The cardiologist or emergency physician measured the ejection fraction (EF) during the period the patient received NIPPV.

2.4. Definitions

Weaning success: After discontinuing NIPPV, the patient wasn’t decided to reintroduce bilevel positive airway pressure (BIPAP) or undergo endotracheal intubation within 24 hours.

Weaning failure: After stopping NIPPV, the patient was decided to reintroduce BIPAP or undergo endotracheal intubation within 24 hours.

2.5. Statistical analysis

Twenty-eight (77.8%) patients had successful weaning from NIPPV, and eight (22.2%) patients had weaning failure, based on our pilot study. The ratio of success to failure to wean from NIPPV was 2.5:1.

STATA software version 14.0 was used to calculate the required sample size by using a two-sample comparison of success and failure to wean from NIPPV. The assumptions were as follows: alpha = 0.05 (two-sided test), the power of the sample size = 0.8, the ratio of the sample size = 2.5:1 and the level of statistical significance was < 0.05. The minimum number of patients required to determine statistical significance for each variable was calculated. A sample size of 247 was required for patients in the NIPPV weaning success group, and a sample size of 99 was required for patients in the NIPPV weaning failure group.

Data were analyzed using STATA version 14.0. The findings are presented as mean standard deviation, frequency (%), or median (inter quartile range). All study variables were compared between the NIPPV weaning success group and the NIPPV weaning failure group using the exact probability test for categorical variables and the t-test for continuous variables. The predictive power of each variable was calculated using univariate logistic regression and presented as the area under the receiver operating characteristic (ROC) curve of model in predicting the risk of weaning failure from NIPPV in emergency department. Circle: The measures of calibration.
Table 1: Comparing the baseline characteristics of participants between cases with and without successful weaning from non-invasive positive pressure ventilation (NIPPV)

| Characters                                      | Successful (248) | Unsuccessful (107) | P value |
|-------------------------------------------------|------------------|--------------------|---------|
| **Age (years)**                                 |                  |                    |         |
| Mean ± SD                                       | 75.1 ± 12.5      | 78.1 ± 11.1        | 0.011   |
| < 60 years                                      | 35 (14.1)        | 6 (5.6)            |         |
| 60-75 years                                     | 67 (27.0)        | 23 (21.5)          | 0.017   |
| > 75 years                                      | 146 (58.9)       | 78 (72.9)          |         |
| **Gender**                                      |                  |                    |         |
| Male                                            | 92 (37.1)        | 28 (26.2)          | 0.051   |
| **Underlying disease**                          |                  |                    |         |
| Asthma/COPD                                     | 25 (10.1)        | 14 (13.1)          | 0.460   |
| Bronchiectasis                                  | 5 (2.0)          | 1 (0.9)            | 0.673   |
| Congestive heart failure                        | 70 (28.2)        | 31 (29.0)          | 0.898   |
| Ischemic heart diseases                         | 118 (47.6)       | 39 (26.5)          | 0.062   |
| Valvular heart diseases                         | 86 (34.7)        | 42 (39.3)          | 0.470   |
| Chronic renal failure                           | 119 (48.0)       | 48 (44.9)          | 0.643   |
| Neoplasm                                        | 26 (10.5)        | 10 (9.4)           | 0.849   |
| Diabetes mellitus                               | 135 (54.4)       | 57 (33.3)          | 0.908   |
| Hypertension                                    | 206 (83.1)       | 91 (83.1)          | 0.755   |
| **Initial vital signs**                         |                  |                    |         |
| Respiratory rate (/min)                         | 28.8 ± 5.9       | 29.3 ± 7.4         | 0.480   |
| Systolic blood pressure (mmHg)                  | 156.4 ± 34.4     | 148.2 ± 32.2       | 0.036   |
| Diastolic blood pressure (mmHg)                 | 82.0 ± 16.8      | 76.4 ± 14.2        | 0.003   |
| Heart rate (bpm)                                | 93.8 ± 22.6      | 94.7 ± 22.1        | 0.739   |
| Body temperature (°C)                           | 36.9 ± 0.7       | 37.1 ± 0.9         | 0.013   |
| SpO2 (%)                                        | 92.0 ± 7.8       | 91.2 ± 7.4         | 0.378   |
| **Vital signs before weaning**                  |                  |                    |         |
| Respiratory rate (/min)                         | 21.8 ± 2.2       | 22.5 ± 2.8         | 0.023   |
| RR > 26 breaths/min                             | 9 (3.6)          | 9 (8.4)            | 0.056   |
| Systolic blood pressure (mmHg)                  | 139.6 ± 24.0     | 139.4 ± 23.5       | 0.936   |
| Diastolic blood pressure (mmHg)                 | 73.9 ± 13.4      | 72.6 ± 14.1        | 0.390   |
| Heart rate (bpm)                                | 80.5 ± 17.0      | 84.0 ± 18.1        | 0.065   |
| Heart rate > 80 bpm                             | 117 (47.2)       | 62 (57.9)          | 0.040   |
| Body temperature (°C)                           | 36.9 ± 0.7       | 37.2 ± 0.4         | 0.268   |
| SpO2 (%)                                        | 98.8 ± 1.7       | 98.4 ± 2.1         | 0.054   |
| SpO2 < 97%                                      | 28 (11.3)        | 19 (17.6)          | 0.072   |
| **Laboratory values**                           |                  |                    |         |
| White blood cell count (cell/mm3)               | 8810.4 ± 5397.5  | 9083.8 ± 4426.0    | 0.645   |
| Hemoglobin (g/dL)                               | 10.8 ± 2.4       | 10.4 ± 2.1         | 0.073   |
| Hematocrit (%)                                  | 32.8 ± 7.5       | 32.7 ± 6.2         | 0.165   |
| Creatinine (mg/dL)                              | 2.2 ± 2.7        | 1.7 ± 1.3          | 0.095   |
| Blood urea nitrogen (mg/dL)                     | 33.0 ± 22.0      | 31.0 ± 18.8        | 0.415   |
| Sodium (mmol/L)                                 | 137.1 ± 5.9      | 136.1 ± 5.7        | 0.167   |
| Potassium (mmol/L)                              | 4.3 ± 0.6        | 4.2 ± 0.7          | 0.409   |
| Pro-BNP (pg/ml)                                 | 5771 (2245 - 11408) | 4774 (2339 -12108) | 0.819   |
| Troponin change > 20% (0, 3 h)                   | 37 (21.4)        | 8 (11.8)           | 0.099   |
| **NIPPV**                                       |                  |                    |         |
| Door to NIPPV (h)                               | 0 (0 - 1)        | 1 (0 - 2)          | 0.093   |
| Duration of NIPPV (h)                           | 6 (4 - 11)       | 8 (4 - 13)         | 0.248   |
| **Initial setting of NIPPV**                    |                  |                    |         |
| PSV (cmH2O)                                     | 13.2 ± 1.9       | 13.1 ± 1.5         | 0.736   |
| PEEP (cmH2O)                                    | 6.7 ± 0.8        | 6.7 ± 0.8          | 0.706   |
| FiO2                                           | 0.4 ± 0.2        | 0.4 ± 0.2          | 0.642   |
| **Setting of NIPPV before weaning**             |                  |                    |         |
| BiPAP mode before NIPPV                         | 165 (66.5)       | 80 (74.8)          | 0.135   |
| PSV (cmH2O)                                     | 12.4 ± 2.3       | 12.3 ± 2.4         | 0.582   |
### Table 1: Comparing the baseline characteristics of participants between cases with and without successful weaning from non-invasive positive pressure ventilation (NIPPV)

| Characters                                      | Successful (248) | Unsuccessful (107) | P value |
|------------------------------------------------|------------------|--------------------|---------|
| CPAP mode before NIPPV                         | 69 (27.8)        | 26 (24.3)          | 0.517   |
| PEEP (cmH2O)                                  | 6.5 ± 1.1        | 6.5 ± 1.0          | 0.924   |
| FIO2                                           | 0.4 ± 0.1        | 0.4 ± 0.1          | 0.189   |
| **Diuretic usage**                             |                  |                    |         |
| Dose of diuretic (mg)                          | 80 (40 -120)     | 80 (40 -120)       | 0.295   |
| Urinary output (ml)                            | 1500 (1100 -2200)| 1300 (800 - 2000) | 0.041   |
| Urinary output/h (ml/h)                        | 236.5 (150 - 394)| 165 (100 - 300)   | 0.001   |
| Urinary output < 150 cc/h                      | 57 (23.0)        | 58 (48.7)          | <0.001  |
| **Ejection fraction**                          |                  |                    |         |
| ≥ 50%                                          | 82 (38.1)        | 47 (48.0)          | 0.206   |
| 41-50%                                        | 54 (25.1)        | 24 (24.5)          |         |
| ≤ 40%                                         | 79 (36.7)        | 27 (27.6)          |         |
| **Functional class (NYHA)**                    |                  |                    |         |
| 1                                              | 2 (0.8)          | 0 (0.0)            | 0.632   |
| 2                                              | 30 (12.1)        | 14 (13.1)          |         |
| 3                                              | 130 (52.4)       | 50 (46.7)          |         |
| 4                                              | 86 (34.7)        | 43 (40.2)          |         |
| **Comorbidities**                              |                  |                    |         |
| Pneumonia                                      | 22 (8.9)         | 26 (24.3)          | <0.001  |
| Anemia                                         | 73 (29.4)        | 41 (38.3)          | 0.108   |
| Volume overload                                | 70 (28.2)        | 22 (20.6)          | 0.147   |
| Tracheobronchitis                              | 7 (2.8)          | 8 (7.3)            | 0.079   |
| Asthma/COPD                                    | 12 (4.8)         | 10 (9.4)           | 0.148   |
| Sepsis                                         | 17 (6.9)         | 15 (14.0)          | 0.042   |
| Acute renal failure                            | 50 (20.2)        | 24 (22.4)          | 0.670   |
| **Arterial blood gases before NIPPV**           |                  |                    |         |
| Arterial pH                                    | 7.40 ± 0.09      | 7.41 ± 0.06        | 0.661   |
| PaCO2 (mmHg)                                  | 37.6 ± 14.7      | 33.7 ± 7.4         | 0.369   |
| PaO2 (mmHg)                                   | 104.0 ± 71.0     | 103.7 ± 58.1       | 0.989   |
| HCO3 (mmol/L)                                 | 21.7 ± 5.3       | 22.8 ± 4.5         | 0.323   |
| Lactate (mmol/L)                              | 2.6 ± 2.1        | 2.3 ± 2.0          | 0.667   |
| **Arterial blood gases before weaning from NIPPV (≤ 90 min)** |                  |                    |         |
| Arterial pH                                    | 7.44 ± 0.0       | 7.41 ± 0.01        | 0.103   |
| PaCO2 (mmHg)                                  | 40.5 ± 11.8      | 42.8 ± 12.0        | 0.562   |
| PaO2 (mmHg)                                   | 116.1 ± 52.5     | 152.3 ± 99.4       | 0.133   |
| HCO3 (mmol/L)                                 | 25.8 ± 5.8       | 26.2 ± 6.6         | 0.827   |
| Lactate (mmol/L)                              | 1.4 ± 1.0        | 1.5 ± 0.7          | 0.682   |

Data are presented as mean ± standard deviation (SD), frequency (%), and median (Inter quartile range).

SD: standard deviation, COPD: Chronic Obstructive Pulmonary Disease, bpm : beats per minute, RR: Respiratory rate, h: hours, Pro-BNP: Pro B-type natriuretic peptide, NIPPV: non-invasive positive pressure ventilation, BiPAP: Bi-level Positive Airway Pressure, PSV: Pressure support ventilation, CPAP: Continuous Positive Airway Pressure, PEEP: Positive End Expiratory Pressure, NYHA: New York Heart Association, PaCO2: partial pressure of carbon dioxide, PaO2: partial pressure of oxygen, FIO2: fraction of inspired oxygen.

under the receiver operating characteristic (AUC) curve with 95% confidence intervals (CI).

The potential predictors were categorized into three levels based on multivariable logistic regression. The regression coefficients of each clinical predictor were divided by the smallest coefficient and rounded to the nearest 0 or 0.5. Discrimination in the prediction of successful weaning scores is shown by the area under the ROC curve and 95% CIs. The calibration of the prediction was determined using the Hosmer–Lemeshow goodness-of-fit test, and the number and percentages in each group are presented as the positive likelihood ratio, 95% CIs, and P values.

### 3. Results

#### 3.1. Baseline characteristics of studied cases

395 patients with acute cardiogenic pulmonary edema who were treated with NIPPV and had available information on weaning from NIPPV at the ED were studied. 40 patients were excluded (34 patients received hemodialysis or peritoneal
dialysis during NIPPV, 6 patients had used NIPPV within the previous 24 hours). Finally, 355 patients were enrolled, (248 (69.85%) patients were successfully weaned off NIPPV, and 107 (30.14%) patients were not successfully weaned (intubation or re-use of NIPPV within 24 hours). Table 1 compares the patients’ baseline characteristics between cases with successful and unsuccessful weaning from NIPPV in ED. Older patients had a significantly higher rate of NIPPV weaning failure than younger patients (p = 0.017). There was no statistically significant correlation between NIPPV success or failure and underlying diseases, laboratory results collected 30 minutes after the patient arrived at EDs, the initial setting of NIPPV, setting of NIPPV before weaning, ejection fraction, functional class (New York Heart Association; NYHA), arterial blood gases before NIPPV and before weaning from NIPPV. The comorbidty of pneumonia, and sepsis was associated with a significantly higher incident of weaning failure (p < 0.001, and p = 0.042, respectively). Patients with a heart rate > 80 beats per minute and a respiratory rate > 26 breaths/minutes before weaning from NIPPV had a successful NIPPV weaning rate of 47.2% (p = 0.040) and 3.6% (p = 0.056), respectively. The urine output during the period of NIPPV < 150 cc/hours had a higher incidence in the weaning failure group (46.7% vs. 23%, p < 0.001).

### Table 2: Multivariable logistic regression analysis of risk factors associated with weaning failure of non-invasive positive pressure ventilation (NIPPV)

| Predictors                | OR     | 95% CI     | P value | Coefficient* | Score |
|---------------------------|--------|------------|---------|--------------|-------|
| Age (year)                |        |            |         |              |       |
| < 60                      | 1.00   | Reference  | -       | -            | 0     |
| 60-75                     | 2.04   | 0.70-5.93  | 0.189   | 1.11         | 2.5   |
| > 75                      | 3.10   | 1.15-8.33  | 0.025   | 1.56         | 3.5   |
| Pneumonia                 |        |            |         |              |       |
| No                        | 1.00   | Reference  | -       | -            | 0     |
| Yes                       | 2.72   | 1.39-5.31  | 0.003   | 0.93         | 2     |
| RR > 26 breaths/min       |        |            |         |              |       |
| No                        | 1.00   | Reference  | -       | -            | 0     |
| Yes                       | 2.65   | 0.91-7.73  | 0.075   | 1.45         | 3     |
| HR > 80 bpm               |        |            |         |              |       |
| No                        | 1.00   | Reference  | -       | -            | 0     |
| Yes                       | 1.74   | 1.04-2.91  | 0.033   | 0.46         | 1     |
| O2 saturation < 97%       |        |            |         |              |       |
| No                        | 1.00   | Reference  | -       | -            | 0     |
| Yes                       | 1.88   | 0.94-3.76  | 0.073   | 0.66         | 1.5   |
| Urinary output < 150 cc/h |        |            |         |              |       |
| No                        | 1.00   | Reference  | -       | -            | 0     |
| Yes                       | 2.93   | 1.74-4.91  | < 0.001 | 0.77         | 1.5   |

Coefficients were obtained from multivariable binary logistic regression. The lowest coefficient obtained using multivariable logistic regression was 0.46, and the scores were split into groups of 0.5 points for each risk factor. OR: odds ratio; CI: confidence interval; Reference: reference category. RR: Respiratory rate, HR: Heart rate.

Figure 2: Comparing observed and predicted risks of failure to weaning from non-invasive pressure ventilation (NIPPV) in the studied cases.

#### 3.2. Multivariable logistic regression analysis

In multivariable logistic regression analysis (Table 2), the statistically significant risk factors (p < 0.05) of weaning failure were patients older than 75 years (odds ratio [OR]: 3.1, 95% CI: 1.15–8.33, p = 0.025), pneumonia (OR: 2.72, 95% CI: 1.39–5.31, p = 0.03), pulse rate > 80 bpm before NIPPV (OR: 1.74, 95% CI: 1.04–2.91, p = 0.033), and a urinary output < 150 cc/h while using NIPPV (OR: 2.93, 95% CI: 1.74–4.91, p < 0.001).
In addition, clinically significant risk factors for failure of weaning from NIPPV were age 60 – 75 years, respiratory rate > 26 breaths/min before weaning, and oxygen saturation of < 97% as assessed by pulse oximetry before weaning from NIPPV.

### 3.3. Designing a predictive model

The lowest coefficient obtained using multivariable logistic regression was 0.46, and the scores were split into groups of 0.5 points for each risk factor. As a result, patients aged < 60 years had no points, those aged 60–75 years had 2.5 points, and those aged > 75 years had 3.5 points. Patients with pneumonia had 2 points, those with a respiratory rate > 26 breaths/min before NIPPV had 3 points, those with a pulse rate > 80 bpm before NIPPV had 1 point, and those with an oxygen saturation by pulse oximetry < 97% had 1.5 points, and those with a urinary output < 150 cc/h while using NIPPV had 1.5 points (Table 2). The mean score of patients with unsuccessful weaning from NIPPV were significantly higher (5.37 ± 1.87 vs. 4.0 ± 1.63; p < 0.001). Figure 1(Left) compares the risk scores between cases with and without successful weaning from NIPPV.

To create the model, the failure to weaning risk score from NIPPV was assessed for each patient and the area under the ROC curve was 71.3% (95% CI: 66.0–75.7%) Figure 1(Right). Based on the area under the ROC curve, the cut point of risk score was divided into three categories (Table 3). The low-risk group had a positive likelihood ratio of 0.48 (95% CI 0.33–0.69, P <0.001), the moderate-risk group had a positive likelihood ratio of 0.74 (95%CI 0.52–1.05, P = 0.080), and the high-risk group had a positive likelihood ratio of 3.41 (95%CI 2.39–4.88, P <0.001) for weaning failure (Table 3). Figure 2 compares the observed and predicted risk of failure to wean from non-invasive pressure ventilation in the studied cases.

### 4. Discussion

Although NIPPV is the first-line treatment for acute respiratory distress induced by acute cardiogenic pulmonary edema, evidence and the treatment protocol for this condition are still insufficient. In this study, multivariate analysis showed that the likelihood of failure in weaning from NIPPV among patients with acute cardiogenic pulmonary significantly increased in those aged > 75 years, those with pneumonia, those with a heart rate > 80 bpm before weaning, and those with a urinary output < 150 cc/h during NIPPV use. Other clinically significant risk factors for failure in weaning from NIPPV were age 60 – 75 years, respiratory rate > 26 breaths/min before weaning, and oxygen saturation of < 97% as assessed by pulse oximetry before weaning from NIPPV.

The lowest coefficient obtained using multivariable logistic regression was 0.46, and the scores were split into groups of 0.5 points for each risk factor. As a result, patients aged < 60 years had no points, those aged 60–75 years had 2.5 points, and those aged > 75 years had 3.5 points. Patients with pneumonia had 2 points, those with a respiratory rate > 26 breaths/min before NIPPV had 3 points, those with a pulse rate > 80 bpm before NIPPV had 1 point, and those with an oxygen saturation by pulse oximetry < 97% had 1.5 points, and those with a urinary output < 150 cc/h while using NIPPV had 1.5 points (Table 2). The mean score of patients with unsuccessful weaning from NIPPV were significantly higher (5.37 ± 1.87 vs. 4.0 ± 1.63; p < 0.001). Figure 1(Left) compares the risk scores between cases with and without successful weaning from NIPPV.

To create the model, the failure to weaning risk score from NIPPV was assessed for each patient and the area under the ROC curve was 71.3% (95% CI: 66.0–75.7%) Figure 1(Right). Based on the area under the ROC curve, the cut point of risk score was divided into three categories (Table 3). The low-risk group had a positive likelihood ratio of 0.48 (95% CI 0.33–0.69, P <0.001), the moderate-risk group had a positive likelihood ratio of 0.74 (95%CI 0.52–1.05, P = 0.080), and the high-risk group had a positive likelihood ratio of 3.41 (95%CI 2.39–4.88, P <0.001) for weaning failure (Table 3). Figure 2 compares the observed and predicted risk of failure to wean from non-invasive pressure ventilation in the studied cases.

### 4. Discussion

Although NIPPV is the first-line treatment for acute respiratory distress induced by acute cardiogenic pulmonary edema, evidence and the treatment protocol for this condition are still insufficient. In this study, multivariate analysis showed that the likelihood of failure in weaning from NIPPV among patients with acute cardiogenic pulmonary signifi-
in the ED. Weaning from NIPPV and continuing to evaluate the prognosis of the disease closely in the ED is essential. If there is a likelihood that a patient cannot be weaned successfully from NIPPV, NIPPV must be restarted. Patients at high risk had a 3.41 times greater likelihood of failing to wean off NIPPV. In this situation, NIPPV treatment should be continued until the patient's total risk score falls to moderate or low. Weaning from NIPPV should then be considered with close follow-up.

This study showed that increasing age increased the risk of weaning failure of NIPPV, particularly in patients aged > 75 and 60–75. No studies had shown evidence of an age-related risk factor for weaning failure. Therefore, risk factors for failure of weaning from NIPPV require further investigation.

Falker et al. studied the amount of diuretic administered to patients and found no effect on acute cardiogenic pulmonary edema therapy (17). In our study, the amount of diuretic used was the same in the NIPPV weaning success and failure groups. This finding is because the primary factor affecting patients' dyspnea and the effectiveness of weaning from NIPPV was the volume of urine produced by the patients, not the amount of diuretic administered. In this study, the most significant risk factor for weaning failure of NIPPV was a urinary output < 150 cc/h during NIPPV.

Acute cardiogenic pulmonary edema is caused by an accumulation of fluid in the alveoli and interstitial space (9). If a patient has a urinary output < 150 cc/h in the first 6 hours, diuretics and urinary output are increased to minimize the amount of volume overload. This is consistent with current heart failure therapy guidelines. This study showed that patients with a heart rate > 80 bpm before initiating weaning from NIPPV were more likely to have weaning failure. This finding is because cardiac dysfunction is the source of acute cardiogenic pulmonary edema (1). As a result, an increased heart rate may cause aberrant cardiac function (15). Additionally, there is evidence that the presence of pneumonia leads to the failure of weaning from NIPPV because pneumonia impairs the correction of desaturation (19). This is particularly challenging in individuals who have acute cardiogenic pulmonary disease.

No arterial blood gas risk indicators for weaning failure of NIPPV were identified in this study. Other studies have shown that decreased acidosis enhanced the success rate of NIPPV (15, 20, 21). When dyspnea is decreased, the majority of patients respond to therapy. Additionally, this study's sample size may have been insufficient, which could have resulted in not finding a significant difference.

Momii et al. recommended a protocol for weaning, which included gradually modifying the ventilator mode and decreasing positive pressure every 30 minutes. The median duration of NIPPV was 8 hours, and the interquartile range was 0, which improved the success rate in weaning from NIPPV (22). Positive pressure reduction data were not collected during NIPPV use in our study. There was no procedure for weaning from NIPPV, and the time to ventilator use or the ventilator mode (BIPAP or continuous positive airway pressure (CPAP)) before opting to wean from NIPPV was not associated with the incidence of weaning failure from NIPPV.

5. Limitations

This study has some limitations. This study was conducted at a university-affiliated super tertiary care hospital in Bangkok. Therefore, the patients’ baseline prognostic factors may differ from those at other institutions. Additionally, weaning from NIPPV was required in the ED owing to restricted resources. Before applying these findings to a different situation, other hospital risk ratings (external validation) should be evaluated to determine whether predictive scores are reliable in predicting weaning from NIPPV in patients with acute cardiogenic pulmonary edema. Furthermore, this was a retrospective study. Some data were missing or incomplete, which resulted in incomplete data collection.

6. Conclusion

In patients with acute cardiogenic pulmonary edema under the NIPPV, weaning is associated with a significantly increased risk of failure in ages >75, presence of pneumonia, heart rate > 80 bpm before weaning, and urinary output < 150 cc/h during ventilation. Based on the model designed in this study, patients with score ≤ 3.5 points, 4–5 points, and > 5 had low, moderate, and severe risk of weaning failure, respectively. Weaning of high-risk patients should be postponed until their clinical prediction score shows a moderate or low risk or they should be closely observed after weaning.

7. Declarations

7.1. Acknowledgments

We thank Ellen Knapp, PhD, from Edanz Group (www.edanzediting.com/ac), for editing a draft of this manuscript.

7.2. Authors’ contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; and agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.
7.3. Ethical considerations
This study was approved by the Faculty of Medicine, Committee on Human Rights Related to Research Involving Human Subjects, Ramathibodi Hospital, Mahidol University (COA. NO MURA2020/972). The ethics committee waived obtaining consent for this research as the patients’ medical records were used for data gathering and a statement covering patient data confidentiality and compliance with the Declaration of Helsinki was provided.

7.4. Availability of data and material
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

7.5. Funding Source
No funding was obtained for this study.

7.6. Competing interests
The authors declare that they have no competing interests.

References
1. Collins SP, Mielniczuk LM, Whittingham HA, Boseley ME, Schramm DR, Storrow AB. The use of noninvasive ventilation in emergency department patients with acute cardiogenic pulmonary edema: a systematic review. Ann Emerg Med. 2006;48(3):260-9. e4.
2. Nava S, Carbone G, DiBattista N, Bellone A, Baiardi P, Cosentini R, et al. Noninvasive ventilation in cardiogenic pulmonary edema: a multicenter randomized trial. Am J Respir Crit Care Med. 2003;168(12):1432-7.
3. Masip J, Peacock WE, Price S, Cullen L, Martin-Sanchez FJ, Seferovic P, et al. Indications and practical approach to non-invasive ventilation in acute heart failure. Eur Heart J. 2018;39(1):17-25.
4. Weng C-L, Zhao Y-T, Liu Q-H, Fu C-J, Sun F, Ma Y-L, et al. Meta-analysis: noninvasive ventilation in acute cardiogenic pulmonary edema. Ann Intern Med. 2010;152(9):590-600.
5. Rochwerger B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017;50(2):1602426.
6. Vital FM, Ladeira MT, Atallah AN. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev. 2013(5):Cdx005351.
7. Felker GM, Adams Jr KE, Konstam MA, O’Connor CM, Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J. 2003;145(2 suppl):S18-S25.
8. Adam CT, Vieira CT, Aguiar SdC, Bündchen D, Vieira DSR. [Non-invasive mechanical ventilation weaning protocols: a systematic review]. Fisioter Pesqui. 2017;24(4):453-60. [Portuguese].
9. Gray A, Goodacre S, Newby DE, Masson M, Sampson E, Nicholl J. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med. 2008;359(2):142-51.
10. Grace MP, Greenbaum DM. Cardiac performance in response to PEEP in patients with cardiac dysfunction. Crit Care Med. 1982;10(6):358-60.
11. Dobbe L, Rahman R, Elmassry M, Paz P, Nugent K. Cardiogenic pulmonary edema. Am J Med Sci. 2019;358(6):389-97.
12. Nava S, Hill N. Non-invasive ventilation in acute respiratory failure. Lancet. 2009;374(9685):250-9.
13. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285(26):1441-6.
14. Members: ATF McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24(1):1-131.
15. Duan J, Han X, Bai L, Zhou L, Huang S. Assessment of heart rate, acidosis, consciousness, oxygenation, and respiratory rate to predict noninvasive ventilation failure in hypoxemic patients. Intensive care med. 2017;43(2):192-9.
16. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;37(3):267-315.
17. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797-805.
18. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;364(36):3599-726.
19. Lemyze M, Taufour P, Duhamel A, Temiime J, Nigoe O,
Vangrunderbeeck N, et al. Determinants of noninvasive ventilation success or failure in morbidly obese patients in acute respiratory failure. PloS one. 2014;9(5):e97563.
20. Singh V, Khanna P, Rao B, Sharma S, Gupta R. Outcome predictors for non-invasive positive pressure ventilation in acute respiratory failure. J Assoc Physicians India. 2006;54:361-5.
21. Liengswangwong W, Yuksen C, Thepkong T, Nakasint P, Jenpanitpong C. Early detection of non-invasive ventilation failure among acute respiratory failure patients in the emergency department. BMC Emerg Med. 2020;20(1):80.
22. Momii H, Tashima Y, Kadokami T, Narita S, Yoshida M, Ando S-i. Experience of step-wise protocol using noninvasive positive pressure ventilation for treating cardiogenic pulmonary edema. Eur J Emerg Med. 2012;19(4):267-70.